General
Preferred name
OTAMIXABAN
Synonyms
FXV673 ()
XRP-0673 ()
RPR130673 ()
FXV-673 ()
RPR-130673 ()
XRP0673 ()
P&D ID
PD012208
CAS
193153-04-7
Tags
available
drug candidate
Drug indication
Coronavirus Disease 2019 (COVID-19)
Angina pectoris
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Otamixaban (FXV673) is an anticoagulant that was originally reported by Aventis Pharmaceuticals (Sanofi) . It is a potent and selective direct inhibitor of coagulation factor Xa that is delivered intravenously. The INN record stipulates the (2R,3R) configuration. Virtual docking studies suggest that otamixaban may bind to the serine protease TMPRSS2 , which is linked to host cell entry by a number of viruses, in particular influenza viruses and respiratory viruses such as SARS-CoV-2. Inhibition of TMPRSS2 is being examined for antiviral activity. The TMPRSS2 inhibitory activity of otamixaban is reported in .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
8
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Molecular Weight
446.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
2.42
TPSA
132.21
Fraction CSP3
0.2
Chiral centers
2.0
Largest ring
6.0
QED
0.16
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
F10
Factor Xa
MOA
coagulation factor inhibitor
Therapeutic Class
Antiviral Agents
Pathway
Metabolic Enzyme/Protease
Source data
